Research programme: anti-inducible T-cell co-stimulator monoclonal antibodies - MedImmune/Japan Tobacco

Drug Profile

Research programme: anti-inducible T-cell co-stimulator monoclonal antibodies - MedImmune/Japan Tobacco

Alternative Names: Anti-ICOS

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 10 May 2017 Anti-inducible T-cell co-stimulator monoclonal antibodies is still in preclinical development for Autoimmune disorders and Inflammation in USA and Japan (Japan Tobacco pipeline, May 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top